Health Equity Concerns in People with Sickle Cell Disease and Recurrent Vaso-Occlusive Crises: Results from an International Survey Study
Findings highlight significant health equity concerns and barriers to care for adults with SCD and recurrent VOCs, underscoring unmet needs and the humanistic burden in this population.
Authors
- Nanxin Li (ORCID: https://orcid.org/0009-0006-4412-0997)
- Ashley Valentine
- Adriana Boateng-Kuffour
- Zahra Pakbaz
- Jennifer Drahos
- Antony P. Martin (ORCID: https://orcid.org/0000-0003-4383-6038)
- Melanie Calvert (ORCID: https://orcid.org/0000-0002-1856-837X)
- Anthony Mason
- Farrukh Shah
- Nick Ainsworth
- L. Lilly (ORCID: https://orcid.org/0009-0006-4044-269X)
Institutions
- NHS Blood and Transplant (GB)
- University of California, Irvine (US)
- Cellular Therapeutics (United Kingdom) (GB)
- NIHR Research Delivery Network (GB)
- NIHR Birmingham Biomedical Research Centre (GB)
- Vertex Pharmaceuticals (United States) (US)
- University of Birmingham (GB)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1007/s40801-025-00531-9
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Gilead Sciences
- Patient-Centered Outcomes Research Institute
- Alexion Pharmaceuticals
- Northwestern University
- Vertex Pharmaceuticals
- LifeArc
- UK Research and Innovation
- Anthony Nolan
- Agios Pharmaceuticals
- bluebird bio
- National Institute for Health and Care Research
- Novo Nordisk
- Shionogi
- Swedish Orphan Biovitrum
- Silence Therapeutics
- Novartis Pharma
- European Regional Development Fund